KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBT: 2009-2025

Historic EBT for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$26.4 million.

  • Neogenomics' EBT fell 47.85% to -$26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year decrease of 42.79%. This contributed to the annual value of -$80.7 million for FY2024, which is 16.91% up from last year.
  • As of Q3 2025, Neogenomics' EBT stood at -$26.4 million, which was up 42.40% from -$45.8 million recorded in Q2 2025.
  • Neogenomics' 5-year EBT high stood at $73.4 million for Q2 2021, and its period low was -$53.2 million during Q1 2022.
  • Over the past 3 years, Neogenomics' median EBT value was -$25.7 million (recorded in 2025), while the average stood at -$25.1 million.
  • Over the last 5 years, Neogenomics' EBT had its largest YoY gain of 508.98% in 2021, and its largest YoY loss of 1,142.75% in 2021.
  • Quarterly analysis of 5 years shows Neogenomics' EBT stood at -$44.2 million in 2021, then soared by 42.26% to -$25.5 million in 2022, then skyrocketed by 40.11% to -$15.3 million in 2023, then decreased by 5.51% to -$16.1 million in 2024, then crashed by 47.85% to -$26.4 million in 2025.
  • Its EBT was -$26.4 million in Q3 2025, compared to -$45.8 million in Q2 2025 and -$25.7 million in Q1 2025.